Blog
RSS FeedPosted by Michael Wonder on 17 Nov 2016
NICE approves three quarters of CDF group 1 drugs for routine use
17 November 2016 - More than 75% of treatments in the Cancer Drugs Fund which have been looked at again by ...
Posted by Michael Wonder on 04 Oct 2016
Did it matter that the Cancer Drugs Fund was not NICE? A retrospective review
3 October 2016 - This article reviews the means by which the Cancer Drugs Fund made recent funding decisions for cancer ...
Posted by Michael Wonder on 02 Aug 2016
Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund
2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for ...
Posted by Michael Wonder on 08 Jul 2016
Japan's Eisai weighs legal action in UK cancer drug row
8 July 2016 - Japan's Eisai said on Friday it would consider all options, including possible legal action, to fight delays ...
Posted by Michael Wonder on 09 Mar 2016
At last, NICE to take over the Cancer Drugs Fund
7 March 2016 - The reincarnation of the Cancer Drugs Fund will benefit both NICE and the NHS. ...
Posted by Michael Wonder on 02 Mar 2016
New “managed access” process for Cancer Drugs Fund to go ahead, NHS England confirms
29 February 2016 - NHS England has confirmed that from 1 July its Cancer Drugs Fund will operate on a “managed ...
Posted by Michael Wonder on 26 Feb 2016
ABPI comments on the NHS England's decision for the Cancer Drugs Fund
26 February 2016 - The ABPI is disappointed by today's decision by NHS England that it will continue to push ahead ...
Posted by Michael Wonder on 25 Feb 2016
NHS plan to reassess value of cancer drugs alarms patient groups
26 February 2016 - NHS England backs tighter control on drugs spending, which opponents say would set treatment ‘back by a ...